Estados Unidos -
inglês -
NLM (National Library of Medicine)
zo skin health skin normalizing system therapeutic treatment for red, sensitized skin- salicylic acid kit
zo skin health, inc. - salicylic acid (unii: o414pz4lpz) (salicylic acid - unii:o414pz4lpz) - salicylic acid 20 mg in 1 ml - acne treatment - for the management of acne. - penetrates pores to control acne blemishes.
Israel -
inglês -
Ministry of Health
koate dvi 250
padagis israel agencies ltd, israel - factor viii (human) - powder for solution for injection - factor viii (human) 250 iu/vial - coagulation factor viii - coagulation factor viii - for the treatment of classical hemophilia (hemophilia a) in which there is a demonstrated deficiency of activity of the plasma clotting factor, factor viii . koate-dvi provides a means of temporarily replacing the missing clotting factor in order to control or prevent bleeding episodes, or in order to perform emergency and elective surgery on individuals with hemophilia.
Israel -
inglês -
Ministry of Health
koate dvi 500
padagis israel agencies ltd, israel - factor viii (human) - powder for solution for injection - factor viii (human) 500 iu/vial - coagulation factor viii - coagulation factor viii - for the treatment of classical hemophilia (hemophilia a) in which there is a demonstrated deficiency of activity of the plasma clotting factor, factor viii . koate-dvi provides a means of temporarily replacing the missing clotting factor in order to control or prevent bleeding episodes, or in order to perform emergency and elective surgery on individuals with hemophilia.
Israel -
inglês -
Ministry of Health
koate dvi 1000
padagis israel agencies ltd, israel - factor viii (human) - powder for solution for injection - factor viii (human) 1000 iu/vial - coagulation factor viii - coagulation factor viii - for the treatment of classical hemophilia (hemophilia a) in which there is a demonstrated deficiency of activity of the plasma clotting factor, factor viii . koate-dvi provides a means of temporarily replacing the missing clotting factor in order to control or prevent bleeding episodes, or in order to perform emergency and elective surgery on individuals with hemophilia.
Cingapura -
inglês -
HSA (Health Sciences Authority)
xyntha powder and solvent for solution for injection 1000iu
pfizer private limited - moroctocog alfa (af-cc) - injection, powder, for solution - 1000iu/vial - moroctocog alfa (af-cc) 1000iu/vial
Cingapura -
inglês -
HSA (Health Sciences Authority)
xyntha powder and solvent for solution for injection 2000iu
pfizer private limited - moroctocog alfa (af-cc) - injection, powder, for solution - 2000iu/vial - moroctocog alfa (af-cc) 2000iu/vial
Cingapura -
inglês -
HSA (Health Sciences Authority)
xyntha powder and solvent for solution for injection 250iu
pfizer private limited - moroctocog alfa (af-cc) - injection, powder, for solution - 250iu/vial - moroctocog alfa (af-cc) 250iu/vial
Cingapura -
inglês -
HSA (Health Sciences Authority)
xyntha powder and solvent for solution for injection 500iu
pfizer private limited - moroctocog alfa (af-cc) - injection, powder, for solution - 500iu/vial - moroctocog alfa (af-cc) 500iu/vial
Cingapura -
inglês -
HSA (Health Sciences Authority)
recombinate for injection 1000 iuvial
takeda pharmaceuticals (asia pacific) pte. ltd. - antihemophilic factor (recombinant) - injection, powder, for solution - 1000 iu/vial - antihemophilic factor (recombinant) 1000 iu/vial
Cingapura -
inglês -
HSA (Health Sciences Authority)
recombinate for injection 250 iuvial
takeda pharmaceuticals (asia pacific) pte. ltd. - antihemophilic factor (recombinant); antihemophilic factor (recombinant) - injection, powder, for solution - 250 iu/vial - antihemophilic factor (recombinant) 250 iu/vial; antihemophilic factor (recombinant) 250 iu/vial